Moderna (NASDAQ: MRNA)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Moderna Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Moderna Company Info
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA).
News & Analysis
The healthcare AI market is forecast to top $100 billion a few years from now.
Does this latest surge significantly improve the investment thesis for Moderna?
These stocks are trading at bargain prices right now.
You'd have a lot more money, but only if you resisted the temptation to take the initial profits.
Here are the five best biotech ETFs to invest in right now.
The company's post-pandemic plans are slowly taking shape.
All of these players look cheap considering their long-term prospects.
These headwinds won't impact every single company, but many are affected.
Valuation
Podcast Episodes
Microsoft CEO Satya Nadella talked about his company's doubling down on gaming, which should give gamers and investors pause.
Moderna has got some promising news on the coronavirus vaccine front.
Moderna shares got a boost as the company continued its COVID-19 vaccine trials.
Encouraging news coming out of the biotech regarding its coronavirus vaccine candidate caused its stock to pop.
Earnings Transcripts
MRNA earnings call for the period ending March 31, 2023.
MRNA earnings call for the period ending December 31, 2022.
MRNA earnings call for the period ending September 30, 2022.
MRNA earnings call for the period ending June 30, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.